Introduction: Current guidelines are oriented toward the treatment of Type I Myocardial Infarction (MI) with no established recommendations regarding management of Type II MI. Type II MI is common in clinical practice, especially in the elderly. In-hospital outcomes in the very elderly with Type II MI are unknown.
Methods: A single-centre retrospective analysis of 956 consecutive patients aged >85 years presenting with NSTEMI between 2010-2018 was undertaken. Patients were stratified by Type I vs Type II MI as defined by the 4 th Universal Definition of MI. The primary outcome was all-cause in-hospital mortality.
Results: Of the 956 patients included, 477 (50%) suffered a Type II MI. The initial presentation of those with Type II MI was delirium (34%), sepsis (18%), post-non-cardiac surgery (8.5%) and bleeding/anaemia (7%). Those with Type II MI were much less likely to undergo invasive coronary angiography (2.5 vs 17.0%, p < 0.001) and less likely to be prescribed aspirin (77 vs 84%, p < 0.007). In-hospital mortality was significantly higher in those with Type II MI (21.1 vs 13.5%, p = 0.002). Cox-proportional hazard modelling showed Type II MI was independently associated with in-hospital mortality after adjustment for conventional cardiac risk factors and medical therapy (OR 1.56, 95% CI 1.1-2.2; p = 0.01) but not after adjusting for patients that underwent coronary angiography (OR 0.97, 95% CI 0.97-2.0; p = 0.07).
Conclusion: Type II MI are common in elderly patients and confers a high risk of in-hospital mortality. At present, there is a lack of evidence to risk stratify and guide treatment in this population. Future studies should address whether an invasive strategy reduces the risk of mortality in this high-risk cohort. The CRE8 coronary stent is a novel polymer-free stent design which delivers Amphilimus (sirolimus/fatty acid) via a reservoir design. Has been shown to be non-inferior to current generation stents and may reduce restenosis in diabetic patients. We aim to review the real-world safety and efficacy data from a tertiary referral centre providing cardiology services for approximately 350,000 residents.
A retrospective analysis of a total of 111 patients receiving 147 CRE8 stents deployed between 2017 and 2018 was conducted. Target lesion failure (TLF), a composite outcome of unplanned intervention, target vessel related myocardial infarction and cardiac death), was measured and patient specific endpoints of MACE (composite of all-cause death, myocardial infarction and stroke) and major bleeding were also measured. Outcomes were recorded until the time of writing.
Of the 111 patients (mean age 67.5 ± 12.1 and 72.8% proportion male), 72.1%, 69.4% and 28.8% had hypertension, hyperlipidaemia and diabetes respectively and 55.9% were smokers. Indication for PCI were STEMI (43%), NSTEMI (39%), positive stress test (17%) and unstable angina (12%). Aspirin/clopidogrel was initiated in 89.3% of patients post-PCI with prasugrel and ticagrelor replacing clopidogrel in 8.0% and 2.7% cases respectively. 52% of stents were inserted via radial access. The average stent diameter and length was 3.14 ± 1.68 mm and 20.23 ± 5.96 mm, respectively.
Analysis revealed an incidence of 3.0% TLF with 4.5% MACE and 3.0% major bleeding consistent with previous pre-marketing randomised controlled trials [1] , providing real-world data supporting the safety and efficacy of this novel stent design.
